Novartis Investigative Site

Doral, Florida 33166

0 studies enrolling now · 5 studies all time

What they study most

Atherosclerosis, Heart Failure and Reduced Ejection Fraction, Heart Failure, Reduced Ejection Fraction, Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis

Studies at this site

• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies — Completed
• Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients. — Completed
• Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis — Completed